• Log In
  • Register
  • Home
  • About NMSG
  • Membership
  • Clinical Trials
  • Fellowship
  • Publications
  • Resources
    • Resources
    • Upcoming Neuromuscular Meetings
  • NMSG Meetings
    • 2023 Neuromuscular Study Group Annual Scientific Meeting
    • NMSG Shark Tank 2023
    • Meetings Archive
Skip to content

Neuromuscular Study Group

  • Log In
  • Register
  • Home
  • About NMSG
  • Membership
  • Clinical Trials
  • Fellowship
  • Publications
  • Resources
    • Resources
    • Upcoming Neuromuscular Meetings
  • NMSG Meetings
    • 2023 Neuromuscular Study Group Annual Scientific Meeting
    • NMSG Shark Tank 2023
    • Meetings Archive

Category: Not Yet Recruiting

msg-admin

Arimoclomol in Sporadic Inclusion Body Myositis (Arimoclomol)

Posted on March 15, 2016 by msg-admin

Inclusion body myositis (IBM) is the most common progressive and debilitating muscle disease beginning in persons over 50 years of age. This study will assess the safety and tolerability of Arimoclomol in IBM as compared to placebo over four months of treatment.

Sponsor: Richard Barohn, MD

This entry was posted in MSG Studies, Not Yet Recruiting and tagged . Bookmark the permalink.

Contact Us

Elizabeth Russo Paulk
Neuromuscular Study Group

Privacy Policy

Site Search

Join the Neuromuscular Study Group

© The Neuromuscular Study Group Inc. All rights reserved. Site by Academic Web Pages

Back to Top